• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SU1170970A3
    申请号:SU813367148
    申请日:1981-12-21
    公开日:1985-07-30
    发明作者:Рабе Томас；Бон Хельмут；А.Марторана Пьеро；Нитц Рольф-Эберхард
    申请人:Кассела Акциенгезельшафт (Фирма)；
    IPC主号:
    专利说明:

    where R and W have the indicated meanings
    followed by isolation of the ridiculous product in the form of a base or an acid addition salt.
    1170970
    2. A process for the preparation of pyridazine derivatives of the general formula
    OCH2CHCH2NHCH2CH2NH
    he
    W
    de R, hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, lower alkyl, lower alkenyl, lower apkoxyalkyl, lower apkinyl, cycloalkyl with 3-6 carbon atoms, cycloalkenyl with 5-6 carbon atoms, fengsch, lower alkoxy, lower oxyalkyl-OXY, lower alkoxyalkyl-OXY-, lower alkenyloxy-, lower alkynyloxy group, cycloapcoxyl with 3-6 carbon atoms, phenyl, lower alkoxy, lower alkanoyl, lower acylamino, or NH-CORj group, where Ry is morpholylylpiperidyl, pyrrolidylphenolphenylphenolphenylphenolphenylphenolphenylphenolphenylphenolphenylphenolphenylphenolphenylphenolphenylphenolphenylphenolphenylphenylphenolphenylphenolphenylphenolphenylphenolphenylphenylphenolphenylphenoxyphenylphenoxyphenoxy . a ureido-substituted group;
    R is hydrogen, halogen, hydroxy, nitro, lower alkyl or lower alkoxy or lower alkenyl; K, is hydrogen or lower alkyl
    or lower alkoxy; R is hydrogen or lower alkyl; .
    W is hydrogen, chlorine or bromine of their acid addition salts, characterized in that the general formula IV
    About Wy-l -R,
    where R and W have the indicated meanings;
    T is chlorine or bromine, is reacted with a compound of general formula V,
    ,
    he
    where R, R and R. have the indicated meanings.
    followed by 1M selection of the desired product, in the form of a base or salt,
    one
    This invention relates to a process for the preparation of new pyridazine derivatives having valuable pharmacological properties that can be used in the treatment of cardiovascular diseases.
    The reaction of alkylation of pyridazinylalkylamines by epoxy or halogen derivatives is known to form
    derivatives of ft -oxy-oc-amino-apkyl derivatives of pyridazinoE ClJ.
    The purpose of the invention is to obtain new pyridazine derivatives with valuable pharmacological properties.
    The goal is achieved by the method of obtaining pyridazine derivatives of the general formula 1 OCH2CHCH2M where R is hydrogen, halogen, hydroxy nitrocap, trifluoromethyl, lower alkyl, lower alky NIL, lower alkoxyalkyl, lower alkynyl, cycloalkyl with 3-6 carbon atoms, cycloalkyl with 5-6 carbon atoms, phenyl, lower al koKCRH, lower oxyalkyl SI-, lower alkoxyalkyl SI-, lower alkenyloxy, lower alkynyloxy, cycloalkoxy with 3-6 carbon atoms, phenyl lower alkoxy, lower alkanoyl, lower acylamino or group HN-CO -RJ., Where Ry is morph lynil, pip Eridinyl, pyrrolidinyl or unsubstituted. or substituted ureido group; hydrogen, halogen, hydroxyl nitro, lower alkyl or lower alkoxy, or lower alkenyl; RJ is hydrogen, or lower alkyl, or lower alkoxy; R is hydrogen or lower alkyl; W is hydrogen, chlorine or bromine, or their acid addition salts. The first variant of the method is that the compound of the general formula I, where R, R and Rj have the indicated values; -CH-CH, Z is a group. -CH-CH, -Ha1, "6H where Hal is a halogen, is reacted with a compound of the general formula P1 lg on Vr H2lSCH2CH2NH-4 | j, r, CH2NH where R and W have the indicated meanings, with the subsequent allocation of the desired product as a base or acid addition salt. Another variant of the method is that the compound of the general formula IV, T, where R and W have the indicated meanings; T - chlorine or bromine is subjected. interaction with the compound of the general formula V OCHjCHCHjNHCH CH NH where R, R, and R have the indicated meanings, followed by allocation of the desired product as a base or salt. The reaction of the compounds of the general formulas. P and III is usually carried out in a solvent or dispersant. Such solvents or dispersants are, for example, water, aromatic hydrocarbons such as benzene, toluene, xylene; ketones, such as acetone, methylztilketone; halogenated hydrocarbons, such as chloroform, carbon tetrachloride, chlorobenzene, methylene chloride; ethers, such as tetrahydrofuran and dioxane; sulfoxides, for example dimethyl sulfoxide; tertiary acid amides, such as dimethylformamide and N-methylpyrrolidone. In particular, polar solvents, for example alcohols, are preferred as solvents. Suitable alcohols are, for example, methanop, ethanol, isopropanol, tert-butanol, etc. The reaction is carried out at temperatures from the reflux temperature of the solvent or dispersant used. The reaction often takes place at 60 - 100 ° C. It is advisable to mix the starting compound of the general formula in a 10-fold or even higher molar excess. The molar ratio between the compounds of the general formulas P and III can be from 1: 1: 1: 1 and, if necessary, even more, Reac tion can be carried out also in the presence of acid acceptors, when Z is the group -CH (OH) -СНС1, such as .poTash, soda, tri3TjmaMHH, etc. Without an acid acceptor, hydrohalides of the compounds of the general formula 1 are usually obtained.
    Inorganic and organic acids are suitable for the formation of acid addition salts with compounds of general formula 1. Suitable acids are, for example, hydrogen chloride, hydrogen bromide, O, 5) naphthalene disulfonic acid, phosphoric, nitric, sulfuric, oxalic, lactic, tartaric, acetic, salicylic, benzoic, formic, propionic, pivalic, diethyloxane, and zinc, acetyl, benzoic, formic, propionic, pivalic, diethyl hydroxylnane, and benzoic acid, acetic acid, nitric acid, sulfuric acid, hydrochloric acid, hydrobromic acid, hydrochloric acid, methyl bromide, hydrochloric acid. Pimelinic, fumaric, maleic, block, sulfamic, phenylpropionic, gluconic, ascorbic, isonicotinic, methanesulfonic, p-toluenesulfonic, citric or adipic acid.
    Pharmaceutically acceptable acid addition salts are preferred. They can be obtained in the same way by combining the components, in a suitable diluent or dispersant I
    The compounds of general formula 1 and their acid addition salts possess valuable pharmacological properties. In particular, they have a pronounced -adrenolytic and cardio-selective action, i.e. compounds have a higher degree of specificity when blocking cardiac p-receptors than blocking peripheral / g receptors, for example, receptors in bronchial muscles. Cros: moreover, they have partly strong с-lytic, antiarrhythmic and blood pressure lowering action. Therefore, they are suitable for the treatment of prevention of heart disorders and diseases such as angina pectoris and arrhythmias, as well as for the treatment of hypertension without affecting the lungs.
    The compounds of the general formula 1 are noticeably superior in their pharmacological action to the known compounds with a similar structure.
    Take p1. 4.9 g of N-C3- (0-xnopphenoxy) -2-hydroxyethyl diamine are dissolved in 50 ml of ethanol. A solution of 3.3 g of 4,5-dichloropyriaz dazinone-3 in 50 ml of ethanol is added, the mixture is then boiled for 12 hours. The solution is concentrated in vacuo, the residue is dispersed in a small amount of ethyl acetate, decanted is separated from ethyl acetate, and the resulting residue is recrystallized of. ethanol.
    Get N- 3- (P-chlorophenoxy) -2oxypropyl -N - (4, pore-3-oceanipyridazyl-5) ethylene diamine hydrochloride, 20 yield 78% of theory., So pl. 2} 9 ° C. C, jH ... O, Calculated, Z: C 44.0; H 4,6j
    Ci 26.0; N 13.7; 011.7. Found,%: C 44.4; H 4.8;
    C1 27.7; N 13.5; About 12.2.
    The (o-chlorophenoxy) -2-oxy0-propyl atylenediamine used as the starting material can be obtained as follows: 120 g of ethylenediamine are dissolved in 150 MP of ethanol, a solution of 20 g of chlorophenylglycide ether in 40 mp 5 ethanol is added to this solution and the mixture is boiled 20 h. Then, excess ethylene diamine and ethanol are distilled off in vacuum, and the residue is distilled in vacuum. N-D (o-chlorophenoxy) -2-hydroxypropyl ethylene0 diamine is obtained in the form of an oil distilled
    at 190С / 0,4 mm. Used in ca-. 4,5-dichloro-pyridazinone-3 can be obtained by the known method by the reaction of flour; 5 perchloric acid with hydrazine. PRI mme R 2. 5.1 g (o-ethoxyphenoxy) -2-hydroxypropyl ztilenediamine is dissolved in 50 mp of toluene and 3 g of potash are added. Then 0 with stirring at room
    A solution of 3.6 g of 2-methyl-4,5-dichlorosylridazinone-3 in 50 ml of toluene is added to the temperature and the mixture is boiled for 17 hours while stirring. The mixture is then allowed to cool to room temperature, it is filtered off from the inorganic residue and the filtrate is concentrated in vacuo. The remaining oil, which quickly solidifies, is recrystallized from ethyl acetate. N- (2-methyl-3-oxo-4-chloropyridazyl-5-ethylenediamine) K-C3- (o-ethoxyphenoxy) -2-hydroxypropane 1 is obtained. Yield 8A% of theory., Mp. 120 C. C, H, 5C1N, 0 Vmesleno,%: C 54.5; H 6.3; Ci 9.0; N 14.1; O 16.1. Found,%: C 54.7; H 6.3, C1 9.1 ; N 13.8; O 16.4. Starting materials can be obtained by analogy with Example 1. Example 3: A mixture of 3.8 g of 2, 4 b -trimethylphenylglycide ester and 7 g of L-benzyl-b - (2-butyl-3-oxo-4xporpiridazyl-5) ethylenediamine is boiled in 80 MP of ethanol for 1 h, then the solution is cooled and concentrated in a vacuum. The residue is purified without dissolving in 120 MP of dioxane and then hydrogenated with hydrogen in the presence of palladium on coal at room temperature, then liquidate from the catalyst, the filtrate is concentrated in vacuo, and the residue is recrystallized from ethanol, to give (2, 4, b-trimethylphenoxy) -2-hydroxypropyl —Y- (2-butyl-3-oxo- 4-horpiridazil-5) ethylenediamine. Yield 68% of theory., Mp. CjjHjjCIN O, Calculated,%: C 60.5; C1 8.1; C 60.2; H 7.4; Found, 7 ,: C1 8.3; N 12.7; O 11.3. 4. 5.85 g of N-C3- (n Example of pentyloxyphenoxy) -2-hydroxypropyl 3 of ethylenediamine and 5.0 g of 4,5-dibromopyridazinone-3 boil t in 60 ml of ethane la. The resulting solution is then filtered and concentrated to give a viscous oil. The oily residue is stirred with 100 ml of water and 5-10 m of ethyl acetate and using aqueous 2N. The soda solution is adjusted to a pH of 9.0. This solution is stirred until the oil is completely crystallized, and the resulting solid product is filtered off (5.4 g, i.e. 58% of theory). The resulting substance is percutaneo from ethanol. 4.2 g of H-ChZ- (p-pentyloxyphenoxy) -2oxypropyl JN - (3-hydroxy-4-bromopyridazyl-5) ethylenediamine, etc. are obtained. 173-175 0. C 31.14; H 6.2; Calculated,%: N 11.9; O 13.6; Vg 17.0. Found,%: C 51.0, H 6.3; N 11.5; O 13.9; Bg 16.8. Example 5. 4.13 g of N- (3-phenoxy-2-hydroxypropyl) ethylenediamine and 5.0 g of 4.5 dibromopyrazinone-3 are boiled in 80 ml of anhydrous ethanol for 30 hours. The resulting solution is filtered and the filtrate is evaporated. A semi-solid product remains that is mixed with. 100 ml of water and 10 ml of ethyl acetate. The mixture is adjusted to a pH of 9.0 by adding an aqueous 2N aqueous solution, and the reaction product gradually solidifies. The 3toT product is filtered off and recrystallized from ethanol to give N- (3-phenoxy-2-oxyclopyl) -N - (3-oxo-4-bromopyridazyl-5) -ethylene diamine, m.p. 165С, yield 3.9 g (52% of theor.). C..O, C, 47; H 5.0; Calculated,%: N 14,6; About 12.5; Br 20.9. Found,%: C 46.8; H 4.7; N 14.6; O 12.9; Br 20.8. Example 2 g of N- (4-chloro-3oxopyridazyl-5) ethylenediamine and 1, 95 g of o-chlorophenylglycidyl ether in 20 mp of anhydrous ethanol are stirred for 24 hours at room temperature, then for 40 hours at reflux .. Then the mixture is cooled and the precipitate is filtered off. The resulting product is recrystallized from ethanol. Obtain 3.1 g (78.3% of Theor.) (O-chlorophenoxy) -2-hydroxypropyl N- (4-chloro-3-oxopyridazyl-5) ethylenediamine, so pl. 170-172 ° C. C, jH, BCl, N, 03 Calculated,%: C 48.24; H 4.86; C1 19.02; N 15.01; About 12.86. Found,%: C 48.3; H 4.8; C1 19.2; N 15.5; About 12.6. The K-4-chloro-3-oxoiarddazyl-5 used, ethylenediamine was prepared as follows.
    To a solution of 400 g of ethylene diamine in 100 MP of absolute ethanol was added 11 g of 4,5-dichloropyridazinone-3 and the mixture was kept in an autoclave for 12 hours at. After cooling, the resulting solution is evaporated to dryness and the residue is recrystallized from ethanol / water. Yield 9 g (71.6% of theor.).
    The N-benzyl-N - (2-butyl-3-oxo 4-chloropyridazyl-5) ethylene diamine used as the starting material can be obtained by analogy with Example 2 by subjecting 2-butyl-4,5-dichloropyridazin-3 to reaction with benzylethylenediamine in the presence of 1 mole of potash in boiling toluene.
    EXAMPLE 7: 4.4 7 4-n-butoxyphenylglycidate ester and 5.6 g of N- (3 x -4-4-bo-p-pyridazyl-5) ethylenediamine are boiled for 1 h with refluxing 80 MP of ethanol. The reaction mixture is then cooled, the solvent is evaporated in vacuo. The resulting residue is dissolved in 100 ml of ethyl acetate, the solution is washed with water and dried with anhydrous magnesium sulfate. By adding dropwise an alcoholic solution of hydrogen chloride to the dried ethyl acetate solution, hydrochloride is obtained. The resulting precipitate is filtered off, washed with a small amount of ethyl acetate and recrystallized twice from ethanol. Yield 7.0 (71% of Theor.) (4butoxyphenoxy) -2-hydroxypropyl JN - (3-oxo-4-bromopyridazyl-5) ethylene diamine hydrochloride, mp. 221 C.
    Calculated,%: C 46.4; H 5.74;
    N 11.4; O 13.02; The total amount of halide is 23.5.
    Found,%: C 46.5; H 5.70; N 11.5; O 12.2; The total number of halo ida is 23.4.
    Example 4.3 g 1- (2,4-dimethylphenoxy) -3-chloropropan-2-ol, 5.9 g N- (2-methyl-3-oxo-4-bromopyridazyl- .5) ethylenediamine and 2.1 g Potash in 100 MP of ethanol is stirred for 2 hours at 35-40 ° C, then boiled for 1 hour with a reverse fridge. The reaction mixture is filtered off in hot form, then it is cooled, and the solvent is evaporated in vacuo. The resulting precipitate is dissolved in 100 ml of ethyl acetate, the solution is washed with water and dried with anhydrous magnesium sulfate. By adding dropwise an alcoholic solution of hydrogen chloride to the dried ethyl acetate solution, the reaction product is precipitated as hydrochloride. The resulting precipitate is filtered, washed with a small amount of ethyl acetate and recrystallized twice from ethanol. The resulting hydrochloride is triturated with 25 ml of soda solution and dispersed for 1 hour at room temperature. Then the suspension is filtered, washed with distilled water until neutral, the residue from the filter is dried, to obtain 5.3 g (57% of theory.) (2,4dimethylphenoxy) -2-oxypropyl -N - (2methyl-3-oxo-4- bromopyridazyl-5) these lendiamine, so pl. .
    .-
    Calculated,%: C 50.8; H 5.9;
    N 13.2; O 11.3; Вг 18,8.
    Found,%: C 51, OH 6.0;
    N 13.0; O 11.1; Вг 18,5.
    Example 9. 4.6 g of 4-chloro-2-ethoxyphenylglycidate ester and 3.7 g of N- (3-oxopyridazyl-5) ethylenediamine are boiled for 1 h with refluxing 80 MP of ethanol. Then the reaction mixture is cooled, the solvent is evaporated in vacuum. The resulting residue was dissolved in 100 MP of ethyl acetate, the solution was washed with water and dried with anhydrous magnesium sulfate. By adding dropwise an alcoholic solution of hydrogen chloride to the dried ethyl acetate solution, the reaction product is precipitated from the hydrochloride form. The resulting precipitate is filtered, washed with a small amount of ethyl acetate and recrystallized twice from ethanol. The resulting hydrochloride is triturated with 25 MJI soda solution and dispersed for 1 hour at room temperature. Then the suspension is filtered, washed with distilled water until neutral, the residue on the filter is dried. Obtain 4.8 g (65% of theory.) (4-. Chloro-2-ethoxyphenoxy) -2-hydroxypropyl N- (Z-oxopyridazyl-5) -ethylene diamine so pl. 168C.
    Calculated,%: C 55.63; H 6.32; N 15.27; O 13.09; C1 9.68. C 55.7; H 6.4; Found,% N, 15.2; O 13.0; C1 9.5. p 10. 4.9 g of N-GB - ((for example, chlorophenoxy) -2-hydroxypropyl} ethylenediamine amine is dissolved in 50 ml of ethanol. Then a solution of 2.9 g of 2-methyl-5-chloropyridazinone-3 is added 50 ml of ethanol and the mixture is boiled under reflux for 12 hours.The mixture is then concentrated in vacuo, the residue is then diluted with a small amount of ethyl acetate, filtered off from ethyl acetate, and the residue on the filter is washed with a small amount of fresh ethyl acetate. Called from ethanol to give 5.7 N- 3- (o-chlorophenoxy) -2-hydroxypropyl M- {2-methyl-3-o xopyridazyl-5) ethylene diamine hydrochloride, so pl. 200-205 C (with decomp.). C ,, C 49.3; Ff 5.70; Calculated,%: C1 18.2; N 14.4; About 12.3. Found,%: C 49.5; H 5.5; C1 18.5; N 14.0; About 12.1. Used as the starting material, 2-methyl-5-chloropyridazinone can be obtained by decarboxylation of 2-methyl-5-chloropyridazin-3on-6-carboxylic acid or by reacting 2-methyl-5-methoxypyridaine-3-with phosphorooxychloride Example 11. g of phenylglycid ether and 3.7 g of M- (H-mon-phyllo-; zil-5) ethylenediamine are boiled; the mixture is refluxed in 80 ml of ethanol. The reaction mixture is then cooled and the solvent is evaporated in vacuo. The resulting residue is dissolved in 100 ml of ethyl acetate, the solution is washed with water and dried with anhydrous magnesium sulfate. By adding dropwise an alcoholic solution of hydrogen chloride to the dried ethyl acetate solution, the reaction product precipitates as a hydrochloride. The precipitate is filtered off, washed with a small amount of ethyl acetate and recrystallized twice from ethanol. Polucheniy hydrochloride is ground in a mortar with 25 mp2n. soda solution and dispersed for 1 hour at room „temperature. Then the suspension is filtered, washed with distilled water with a water until neutral, and the residue from the filter is dried. 3.7 g (61% of theor.) N- (3-phenoxy-2-oxypropyl) - (3-oxopyridazyl-5) ethylenediamine are obtained, m.p. 151-153, C75: C 59.2; H 6.6; Calculated, N 18,4; About 15.8. C, 59.5; H 6.7; Found,%: N 18.1; About 15.5. The N- (3oxopyridazyl-5) ethylenediamine used in this example can be prepared as follows. 15 g of N- (3-oxo-4-chloropyridazh1-5) ethylenediamine are dissolved in 40 ml of methanol, then 1.5 g of palladium-carbon (10%) is added and hydrogenated at room temperature under atmospheric pressure. After the absorption of hydrogen ceases, so much warm water is added so that the reaction product dissolves completely; then the reaction mass is filtered from the catalyst, the clear filtrate is concentrated. The resulting solid is then filtered again and recrystallized from ethanol / water (50:50). Output 11.4 g (75% of theory.) K- (3-oxo-4-chloropyridazyl-5) -ethylene diamine hydrochloride, so pl. 335 ° C. The free base can be obtained from this product by treatment with a dilute soda solution at room temperature. EXAMPLE 12 4.9 g (chlorofenoxy) -2-oxyprosy-1l} ethylenediamine is dissolved in 50 mp of ethanol, a solution of 3.5 g of 5-bromopyridazinone-3 in 50 ml of ethanol is added, and then a mixture of bales t 12 t h with reflux condenser. After that, the mixture is concentrated in vacuo, the residue is dispersed with a small amount of ethyl acetate, filtered from the latter, the residue on the filter is further washed with fresh ethyl acetate. The crystalline product is ground in a mortar with 25 ml of 2N. soda solution and dispersed for 1 h at room temperature. The suspension is stirred together with 50 ml of ethyl acetate for 10 minutes in a high-speed mixer, the slurry is allowed to settle, and the organic phase is separated. The resulting ethyl acetate solution is washed twice with distilled water and dried with anhydrous magnesium sulfate. By adding dropwise
    13
    an alcoholic solution of hydrogen chloride in a dried ethyl acetate solution, the reaction product is precipitated in the form of hydrochloride. The resulting precipitate is filtered, washed with a small amount of ethyl acetate and recrystallized twice from ethanol to obtain 5.3 g of (o-chlorophenoxy) -2-hydroxypropyl J-N- (3-oxopyridazyl-5) ethylene diamine hydrochloride, etc., 219 ° C. C. gN, CbN, 0
    1f
    C 48.00; H 5.4; Calculated
    C1 18.9; N 14.9;
    About 12.8.
    C -48.3; H 5.6;
    Found,% C1 18.5; N 14.5; About 12.5.
    C1
    ( HE
    014
    Output 70% of theor. 5-Bromo-pyridazinone-3 is obtained by reaction of methyl 3-bromo-3-formyl acrylic acid with hydrazine hydrate.
    Likewise, compounds shown in Table 1 are prepared. one.
    The superiority of the proposed compounds over the known compound of the same action and similar chemical structure — metoprolol — is confirmed by the following comparative
    data
    The structure of the compared compounds. The proposed connection:
    NzS-0-CH2-CH2
    0-CH2CHCHN21JCH (CH3) 2 IN
    he Effects of compounds on the blood circulation of anesthetized dogs. Blocking of -receptors. In a dog under pentobarbital anesthesia, the proposed compound inhibits the increase in cardinal force and frequency of heart contractions from prenaline at 0.003 mg / c intravenously, while a similar value for metoprolol is 0.14 mg / kg. Thus, the proposed compound has an effect on the heart about 40 times more actively than metoprolol, and 11 times more active than propranolol. A comparison of the inhibitory effect on the cardiac / 3 receptors and on the / L receptors of the blood vessels ED (heart) / (vessel), which is considered to be the cardioselectivity criterion, showed a 1:76 ratio for the proposed compound and 1: 18 for metoprolol. Thus, the cardioselective effect of the proposed compound is noticeably higher. Hemodynamics. The hemodynamic profile of the effect of the proposed compound on a dog under pentobarbitapal anesthesia is characterized by a noticeable decrease in blood pressure (-35 mm Hg at 0.05 mg / kg intravenously, for metoprolol 5 mm Hg), presistolic pressure in the left ventricle (LVEDP - 2 mm Hg, metoprolol + 2 mm Hg) and total peripheral resistance to the blood flow (TPR - 1191 dyns. cm, metoprolol - 135 dyns. cm) without simultaneous decrease in contractility of the heart, which is strongly expressed by the action of metoprolol, especially when you sokih doses. Reducing contractility and cardiac performance when using the proposed compound prevents moderate internal sympathicomimetic activity (ISA), which is about 3 times lower than y of pindolol. Thus, the proposed compound has a more favorable hemodynamic profile of action than metoprrolol, since, on the one hand, by reducing the total peripheral resistance, it reduces the load on the heart during expulsion, and on the other hand, reduces the load on the heart during filling, without negative inotropic action. Effect on the awake dog with renal hypertension. Metoprolol at a dose of 3.0 mg / kg is almost not orally; nc / fHgO listed in the table. The 2 values of intrinsic sympathicomimetic activity (ISA) are set relative to pindolol, which is considered as a reference. Pharmacological data show that the proposed compounds, compared with the known ones, differ in a particularly favorable spectrum of action. In addition to the blocking effect, which is increased by at least 100% compared with known concentrations, the main advantage of the proposed compounds is a decrease in blood pressure, in particular, a very balanced inner sympathetic 11 causes an ostf5 compound of the formula OCHxCH-CH HCH CH CH 3HD x1 IN 0 lowering blood pressure in an awake dog with renal hypertension (l blood pressure. syst. 6 mmHg, 4 blood, pressure 3x3 mm hg.), while the proposed compound is already at a dose of 0.2 mg / kg orally lowers systolic blood pressure at 28 mm Hg. Art. and diastolic - 15 mm Hg. Art. In tab. 2 shows the data obtained from similar tests of other proposed compounds, as well as known and. similar in structure lj N-CH3 metic activity (ISA), which prevents the reduction of heart contractility, but does not cause an undesirable increase in heart rate. In addition, the compatibility of the proposed compounds with tissues is improved. Thus, for example, when administered intravenously, local irritation is largely excluded. The compounds according to the invention are suitable for the treatment and prophylaxis of myocardial infarction. The daily dose for adults is 5-30 mg. It can be taken one at a time or divided into 2-3 doses. The compound is administered orally or intravenously. Table 1

    /-OCH,CHCH,NHCHzCH2NH-C.i,
    w
    -N-r,
    权利要求:
    Claims (2)
    [1]
    1. The method of obtaining pyridazine derivatives of General formula 1
    R 3 is hydrogen, either lower alkyl or lower alkoxyl;
    R * is hydrogen or lower alkyl;
    W is hydrogen, chlorine or bromine, or their acid addition salts, characterized in that, the compound of General formula P where R y , and R 3 have the indicated meanings;
    Z - group
    —CH — CH1 or —CH —CH, —Hat χ θ ″ ″, 0 “where Hal is halogen, is reacted with
    09) SU su 1170970 'by the general formula W where R 4 and W have the indicated meanings, followed by isolation of the target product in the form of a base or an acid addition salt.
    [2]
    2. A method of obtaining pyridazine derivatives of General 'formula 1
    Ri
    W
    OCH 2 CHCH 2 NHCH 2 CH 2 NH where R is hydrogen, halogen, hydroxyl, nitro, trifluoromethyl, lower alkyl, lower alkenyl, lower apoxyalkyl, lower alkynyl, cycloalkyl with 3-6 carbon atoms, cycloalkenyl with 5-6 carbon atoms , phenyl, lower alkoxy, lower hydroxyalkyloxy, lower alkoxyalkyloxy, lower alkenyloxy, lower alkynyloxy, cycloalkoxy with 3-6 carbon atoms, phenyl, lower alkoxy, lower alkanoyl, lower acylamino or NH-C.ORj · group, where R y is morpholipyl, piperidinyl, pyrrolidinyl or unsubstituted or substituted. substituted ureido group;
    R - hydrogen, halogen, hydroxyl, nitro group, lower alkyl or lower alkoxyl group or lower alkenyl;
    F. 3 is hydrogen or lower alkyl or lower alkoxyl;
    R 4 is hydrogen or lower alkyl; .
    W is hydrogen, chlorine or bromine or their acid addition salts, characterized in that the compound of general formula IV o
    where R 4 and W have the indicated meanings; T is chlorine or bromine, is reacted with a compound of general formula V,
    OCH 2 CHCH 2 MCHS 2 CH 2 1 1H g he where R, R - and R, have the indicated meanings, followed by isolation of the target product, in the form of a base or salt.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1170970A3|1985-07-30|Method of producing pyridazine derivatives or their acid-additive salts |
    US4076820A|1978-02-28|Benzoquinolizines and hypotensive compositions containing them
    US4059621A|1977-11-22|Substituted benzamido propanolamines
    IE47812B1|1984-06-27|Alkylenediamine derivatives
    SU841587A3|1981-06-23|Method of preparing derivatives of alkylenediamine or their acid-additive salts
    US4198407A|1980-04-15|Substituted 2-phenyl-1,2,4-triazine-3,5|-diones, and coccidiostatic agents containing same
    US4786642A|1988-11-22|Phenylnaphthyridines containing a methyl substituent in the 3-position useful in the treatment of ulcers
    RU2695383C2|2019-07-23|Bendamustine derivatives, related compounds and their medical application for treating cancer
    US4379160A|1983-04-05|Carbazole compounds and medicinal use thereof
    US4035367A|1977-07-12|Hydroxyalkyl-substituted-amino-quinolines
    US3824271A|1974-07-16|3-alkyl-3-|propionitriles
    US4652566A|1987-03-24|Benzofuran derivatives, processes for preparing the same and antihypertensive agents containing the same
    PL96534B1|1977-12-31|METHOD OF MANUFACTURING NEW DWUBENZO / B, F / TIEPIN
    US3951983A|1976-04-20|Phenoxypropanolpiperazines
    US3989709A|1976-11-02|Fused ring benzimidazole derivatives
    EP0327808B1|1991-05-02|Substituted 3-aminosydnonimines, process for their preparation and their use
    US4353904A|1982-10-12|Phenylpiperazine derivatives of 1,3,4-oxadiazolylphenols, and therapeutic agents containing these compounds
    SU1549480A3|1990-03-07|Method of producing derivatives of iminothiazolidine or their hydrochlorides
    EP0687256B1|1997-09-03|Hydroxymethyl furazane carboxylic acid derivatives and their use in the treatment of cardio-vascular conditions
    US3957791A|1976-05-18|Hydroxyalkyl-piperazino-quinoline nitrates
    US4499105A|1985-02-12|Carboxyimidamide derivatives
    SU936811A3|1982-06-15|Process for producing pyridazinylhydrazones or their acid additive salts
    GB2125404A|1984-03-07|Thiazole derivatives
    SU856385A3|1981-08-15|Method of preparing derivatives of 3-|pyridazine or their sals
    US3941798A|1976-03-02|5-Alkyl-3-|-1,3,4-oxadiazolin-2-one compounds
    同族专利:
    公开号 | 公开日
    EP0054946A1|1982-06-30|
    RO84277B|1984-07-30|
    NO814182L|1982-06-23|
    DE3165595D1|1984-09-20|
    ES8400096A1|1983-10-16|
    EP0054946B1|1984-08-15|
    KR830007577A|1983-11-04|
    DE3048487A1|1982-07-29|
    PL234312A1|1983-02-14|
    FI73418C|1987-10-09|
    DK149810B|1986-10-06|
    FI73418B|1987-06-30|
    RO88201B|1985-12-31|
    IL64605D0|1982-03-31|
    AU7870481A|1982-07-01|
    CS236665B2|1985-05-15|
    AT8991T|1984-09-15|
    CA1173033A|1984-08-21|
    IL64605A|1985-11-29|
    PL238538A1|1983-04-25|
    DK542881A|1982-06-23|
    RO84277A|1984-05-23|
    PH17529A|1984-09-13|
    ES8308859A1|1983-10-01|
    PT74185B|1987-03-24|
    ES518139A0|1983-10-01|
    SG7585G|1985-08-08|
    GR81382B|1984-12-11|
    IE51985B1|1987-05-13|
    PL137106B1|1986-04-30|
    RO88190B|1985-12-31|
    HK51485A|1985-07-12|
    PL238537A1|1983-06-20|
    JPS57128677A|1982-08-10|
    ES508274A0|1983-03-16|
    ES518138A0|1983-10-16|
    PT74185A|1982-01-01|
    FI813941L|1982-06-23|
    DD202013A5|1983-08-24|
    SU1151204A3|1985-04-15|
    US4532239A|1985-07-30|
    IE813014L|1982-06-22|
    RO88201A|1985-12-30|
    ZA818806B|1982-11-24|
    AU544386B2|1985-05-23|
    KR880002233B1|1988-10-20|
    PL136127B1|1986-01-31|
    ES8304941A1|1983-03-16|
    RO88190A|1985-12-30|
    DK149810C|1987-03-23|
    PL137150B1|1986-05-31|
    NZ198919A|1985-05-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4783462A|1985-02-27|1988-11-08|Nissan Chemical Industries Ltd.|3pyridazinone, and anti-allergic agent containing it|
    US4892947A|1985-04-27|1990-01-09|Nissan Chemical Industries Ltd.|3Pyridazinone, process for its preparation and anti-allergic agent containing it|CA957364A|1968-11-18|1974-11-05|Pfizer Corporation|Preparation of polar-substituted phenyl propanolamines|
    GB1421999A|1973-02-08|1976-01-21|Smith Kline French Lab|Heterocyclic containing sulphoxides|
    US4115575A|1973-02-20|1978-09-19|Ciba-Geigy Corporation|2--pyrazines|
    GB1488330A|1973-12-19|1977-10-12|Smith Kline French Lab|Dihydropyridazinones|
    US4088764A|1973-12-27|1978-05-09|Cassella Farbwerke Mainkur Aktiengesellschaft|Pharmaceutically active derivatives of 1-phenoxy-3-amino-propan-2-ol|
    CH592625A5|1974-05-14|1977-10-31|Ciba Geigy Ag|
    LU77339A1|1977-05-16|1979-01-19|
    DD146749A3|1977-12-01|1981-03-04|Dieter Lehmann|PROCESS FOR THE PREPARATION OF PHENOXYALKANOLAMINE DERIVATIVES|
    DE3023369A1|1980-06-23|1982-01-14|Boehringer Mannheim Gmbh, 6800 Mannheim|ARYLOXYPROPANOLAMINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|DE3023369A1|1980-06-23|1982-01-14|Boehringer Mannheim Gmbh, 6800 Mannheim|ARYLOXYPROPANOLAMINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|
    JPS61282194A|1985-06-06|1986-12-12|Yukio Nakamura|Propeller shaft for jet propulsion type craft and manufacture thereof|
    JPH0629254B2|1986-09-08|1994-04-20|帝国臓器製薬株式会社|Pyridazinone derivative|
    DE3902316A1|1989-01-26|1990-08-02|Lentia Gmbh|Novel piperazinylalkyl-3-pyridazinones, process for their preparation and their use as hypotensive agents|
    NZ234087A|1989-06-19|1991-08-27|Teikoku Hormone Mfg Co Ltd|2-)-2-methylpropyl- aminophenyl pyridazine derivatives|
    US5221674A|1989-06-19|1993-06-22|Teikoku Hormone Mfg. Co., Ltd.|Pyridazinone derivatives|
    HU214320B|1991-12-20|1998-03-02|EGIS Gyógyszergyár Rt.|Process for producing novel 3-pyridazinon derivatives and pharmaceutical compositions producing them|
    WO1999064402A1|1998-06-05|1999-12-16|EGIS Gyógyszergyár Rt.|Process for the preparation of a 3-pyridazinone- 4-substituted amino- 5-chloro- derivative|
    US8232274B2|2007-03-15|2012-07-31|Albany Molecular Research, Inc.|Pyridazinone derivatives useful as glucan synthase inhibitors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE19803048487|DE3048487A1|1980-12-22|1980-12-22|BASICLY SUBSTITUTED PYRIDAZINE, THEIR PRODUCTION AND THEIR USE|
    [返回顶部]